Physician profile
Robert B Rhodes
NPI 1912009978
$323.78
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $93.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $69.74 | 2020 | |
| Amgen INC. | $64.70 | 2019 | |
| Sunovion Pharmaceuticals INC. | $50.66 | 2019 | |
| Boston Scientific Corporation | $38.03 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $33.99 | 2019 | |
| Allergan, INC. | $26.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.78 | 2019 | |
| Genentech USA, INC. | $12.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rhodes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.